OncoMatch/Clinical Trials/NCT07227415
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Is NCT07227415 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including PF-08634404 and Ipilimumab for carcinoma, renal cell.
Treatment: PF-08634404 · Ipilimumab · Axitinib — This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Prior therapy
Cannot have received: systemic therapy for RCC
Exception: immunotherapy after surgery allowed if received >12 months prior
No prior systemic therapy for RCC (immunotherapy after surgery is allowed if received >12 months prior)
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Tennessee Oncology, PLLC-Dickson · Dickson, Tennessee
- Tennessee Oncology, PLLC- Franklin Proton Center · Franklin, Tennessee
- Tennessee Oncology, PLLC-Franklin · Franklin, Tennessee
- Tennessee Oncology, PLLC-Gallatin · Gallatin, Tennessee
- Tennessee Oncology, PLLC-Hendersonville · Hendersonville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07227415 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy for RCC disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages